While last week’s recommended changes by CDC advisors to the MMRV vaccine schedule are unlikely to have a tangible effect on ...
An advisory committee last year found that Zynquista’s benefit-risk profile in type 1 diabetes was unfavorable due to cases ...
By improving gait stability, Ionis’ zilganersen could be “potentially disease modifying,” according to analysts at William ...
In its rejection letter, the FDA flagged problems at a third-party fill-finish site owned by Novo Nordisk. Issues at this ...
The agency has also pointed to the use of Tylenol and other acetaminophen products during pregnancy as potentially linked to ...
Small and large drugmakers alike have made big, proactive moves to secure the production capacity that will be vital to ...
The company was expecting a decision from the FDA by Sept. 28 for its oral drug tolebrutinib, but an update to the drug’s ...
MapLight Therapeutics, the second biotech to launch a Nasdaq bid this month, is a neuro-focused company advancing treatments ...
The acquisition of breakout obesity star Metsera should pump new life into Pfizer's portfolio, which over the last two years ...
In an interview with German-language outlet Neue Zuercher Zeitung, Novartis CEO Vas Narasimhan said the company is exploring ...
For the last two years, Keytruda has reigned as the world’s top-selling drug—a distinction under threat with key patent ...
With AbbVie’s $1.2 billion acquisition of Gilgamesh Pharmaceuticals’ lead depression drug, the psychedelic therapeutics space ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback